Home/Filings/4/0001479290-18-000050
4//SEC Filing

Browne L Daniel 4

Accession 0001479290-18-000050

CIK 0001479290other

Filed

Mar 15, 8:00 PM ET

Accepted

Mar 16, 8:03 PM ET

Size

12.7 KB

Accession

0001479290-18-000050

Insider Transaction Report

Form 4
Period: 2018-03-15
Browne L Daniel
DirectorCEO and President
Transactions
  • Sale

    Common Stock

    2018-03-16$31.43/sh5,452$171,348141,875 total
  • Exercise/Conversion

    Common Stock

    2018-03-16$2.55/sh+20,000$51,000147,327 total
  • Exercise/Conversion

    Common Stock

    2018-03-16+20,0000 total
    Exercise: $2.55Exp: 2018-04-29Common Stock (20,000 underlying)
  • Sale

    Common Stock

    2018-03-15$32.80/sh1,000$32,800130,208 total
  • Tax Payment

    Common Stock

    2018-03-15$31.65/sh2,881$91,184127,327 total
Holdings
  • Common Stock

    (indirect: See footnote)
    409
Footnotes (5)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Browne.
  • [F2]Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2016 Restricted Stock Award ("RSA") for 25,000 shares. The RSA vests in three equal annual installments from March 15, 2016, subject to Mr. Browne's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
  • [F3]The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $31.975. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F4]These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.
  • [F5]The Option is fully vested as of April 28, 2012.

Issuer

Revance Therapeutics, Inc.

CIK 0001479290

Entity typeother

Related Parties

1
  • filerCIK 0001597583

Filing Metadata

Form type
4
Filed
Mar 15, 8:00 PM ET
Accepted
Mar 16, 8:03 PM ET
Size
12.7 KB